Volume 3, Issue 10

Clinical Approaches and DMT Choices

In this issue:

As the number of new MS therapies continues to grow, so does the uncertainty about which management approach — escalation or highly effective disease-modifying therapy — is best for each patient. What are the patient-specific factors that indicate the most appropriate DMT selection? What’s known about the potential longer-term risks associated with highly effective therapies? 

That’s the focus of our discussion with Dr. Yujie Wang from the University of Washington and Johns Hopkins University, and Dr. Anne Damian-Yacoub from Johns Hopkins University in this eMultipleSclerosis Review podcast. 

Learning objectives:

  • Discuss patient-specific factors that help define the most appropriate treatment approach and DMT selection. 
  • Describe the potential risk profiles that may be associated with specific highly effective therapies as compared to modestly effective therapies. 

Authors:

Anne Damian Yacoub, MD
Anne Damian Yacoub, MD

Assistant Professor of Neurology
Johns Hopkins University School of Medicine
Baltimore, MD

Yujie Wang, MD
Yujie Wang, MD
Acting Assistant Professor of Neurology
University of Washington
Seattle, WA
Adjunct Assistant Professor of Neurology
Johns Hopkins University
Baltimore, MD

Program Directors:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: March 9, 2021
Expiration date: March 8, 2023